Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily injection reshape bodies of HIV patients?

NCT ID NCT03226821

Terminated Disease control Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether tesamorelin (Egrifta), a daily injection that boosts growth hormone, can improve body composition in people with HIV who have excess belly fat (lipodystrophy). Six participants received the drug for up to 12 months, with researchers measuring liver fat, belly fat, and insulin sensitivity. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tesamorelin (Egrifta) - a daily injection that mimics growth hormone releasing hormone
What this could lead to
If it works, this could help reduce belly fat and improve body shape in people with HIV-related lipodystrophy.
What could go wrong
This is a very small study (only 6 people) that was terminated early, so results may not be reliable. Tesamorelin can cause joint pain, swelling, or injection site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BODY COMPOSITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV-Associated Lipodystrophy Syndrome isolated congenital growth hormone deficiency pituitary dwarfism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BODY COMPOSITION GROWTH HORMONE DEFICIENCY HIV LIPODYSTROPHY SYNDROME

Contacts and locations

Locations

  • Neuroendocrine Unit and Pituitary Center, Columbia University

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.